Mutation profile of diffuse large B-cell lymphoma with relapses in the central nervous system

Introduction. The recurrence of diffuse large B-cell cell lymphoma in the central nervous system in the vast majority of cases is a fatal manifestation of the disease. The study of the lymphoma mutational profile can improve the accuracy of the prognosis of relapse in the central nervous system and justify the selection of patients for preventive treatment. Aim. To evaluate the mutational profile of cases of diffuse large B-cell cell lymphoma with central nervous system damage in relapse based on the results of our own experiment on high-performance sequencing.

Materials and methods. On the Illumina platform, full-exome sequencing of diagnostic samples of diffuse large B-cell cell lymphoma with relapses in the central nervous system was performed. A panel including more than 70 genes was analyzed.

Results. Four main groups of genetic events can be distinguished in the group of studied samples, namely: combined mutations in the NF-kB (MYD88, NOTCH1, CD79B, CARD11) and JAK-STAT (PIM1, STAT6) signaling pathways, as well as aberrations in the main oncosuppressor TP53 and chromatin remodeling system genes (ARID1A, KMT2D, EP300, SMARCA4). A recurrent mutation c. 794T>C, p.L265P MYD88 was detected in the study group. Among other findings, mutations in the CIITA and CD58 genes should be noted, which are important in avoiding tumor cells from immune surveillance.

Conclusion. Despite the apparent heterogeneity of the mutational profile of diffuse large B-cell cell lymphoma with relapses in the central nervous system, in most cases, tumor cells were characterized by genetic disorders leading to the production of a large number of pro-inflammatory cytokines by malignant lymphocytes, as well as aberrations that reduce immunogenicity and contribute to the avoidance of immune surveillance by the tumor.

1. Воропаева Е.Н., Поспелова Т.И., Максимов В.Н. и др. Мутации в генах ARID1A и SMARCA4 при рецидивах диффузной В-крупноклеточной лимфомы с поражением ЦНС. Медицинская генетика 2020;19(6):90-2. DOI: 10.25557/2073-7998.2020.06.90-92

2. Savage K.J. Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies. Hematology Am Soc Hematol Educ Program 2017;2017(1):578-86. DOI: 10.1182/asheducation-2017.1.578

3. Ollila T.A., Olszewski A.J. Extranodal diffuse large B сеЦ Lymphoma: molecular features, prognosis, and risk of central nervous system recurrence. Curr Treat Options Oncol 2018;19(8):38. DOI: 10.1007/s11864-018-0555-8

4. Grimm K.E., O'Malley D.P. Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. Ann Diagn Pathol 2019;38:6-10. DOI: 10.1016/j.anndiagpath.2018.09.014

5. Illerhaus G. CNS relapse in DLBCL: a calculable risk? Blood 2021;137(8):1011-2. DOI: 10.1182/blood.2020009269

6. Hall K.H., Panjic E.H., Valla K. et al. How to decide which DLBCL patients should receive CNS prophylaxis. Oncology (Williston Park) 2018;32(6):303-9.

7. Ma'koseh M., Tamimi F., Abufara A. et al. Impact of Central Nervous System International Prognostic Index on the treatment of diffuse large B cell lymphoma. Cureus 2021;13(8):e16802. DOI: 10.7759/cureus.16802

8. Nagpal S., Glantz M.J. Treatment and prevention of secondary CNS lymphoma. Semin Neurol 2010;30(3):263-72. DOI: 10.1055/s-0030-1255222

9. Voropaeva E., Beresina O., Pospelova T. et al. Mutational profile of diffuse large B-cell lymphoma with central nervous system relapse: analysis of CBioPortal for Cancer Genomics database. 2020 Cognitive Sciences, Genomics and Bioinformatics (CSGB) 2020:190-4. DOI: 10.1109/CSGB51356.2020.9214638.

10. NGS WIZARD by Genomenal. Доступно по: https://www.genomenal.ru/. NGS WIZARD by Genomenal. (In Russ.). Available at: https://www.genomenal.ru/.

11. Gao J., Aksoy B.A., Dogrusoz U. et al. Integrative analysis of complex cancer Genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6(269):pl1. DOI: 10.1126/scisignal.2004088.

12. Jay J.J., Brouwer C. Lollipops in the clinic: information dense mutation plots for precision medicine. PLoS One 2016;11(8):e0160519. DOI: 10.1371/journal.pone.0160519

13. Salem M.E., Bodor J.N., Puccini A. et al. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Int J Cancer 2020;147(10):2948-56. DOI: 10.1002/ijc.33115

14. Ortega-Molina A., Boss I., Canela A. et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med 2015;21:1199-208. DOI: 10.1038/nm.3943. DOI: 10.1038/nm.3943

15. Garbati M.R., Thompson R.C., Haery L., Gilmore T.D. A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity. Cancer Letters 2011;302:76-83. DOI: 10.1016/j.canlet.2010.12.018

16. Hu B., Lin J.-Z., Yang X.-B., Sang X.-T. The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review. Cell Proliferation 2020;00:e12791. DOI: 10.1111/cpr.12791

17. Schmitz N., Nickelsen M., Savage K.J. Central nervous system prophylaxis for aggressive B-cell lymphoma: who, what, and when? Hematol Oncol Clin North Am 2016;30:1277-91. DOI: 10.1016/j.hoc.2016.07.008

18. Karube K., Enjuanes A. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia 2018;32(3):675-84. DOI: 10.1038/leu.2017.251

19. Schmitz R., Wright G.W. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med 2018;378(15):1396-407. DOI: 10.1056/NEJMoa1801445

20. Jardin F. Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy. Discov Med 2014;18(97):51-65.

21. Voropaeva E.N., Pospelova T.I., Voevoda M.I., Maksimov V.N. Frequency, spectrum and the functional significance of mutations in TP53 gene in patients with diffuse large B-cell lymphoma. Mol Biol (Mosk) 2017;51(1):64v72. DOI: 10.7868/S0026898416060227

22. cBioPortal for Cancer Genomics. Available at: https://www.cbioportal.org/.

23. Chapuy B., Stewart C., Dunford A.J. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018;24:679-90. DOI: 10.1038/s41591-018-0016-8

24. Lauw M.I.S., Lucas C.-H.G., Ohgami R.S., Wen K.W. Primary central nervous system lymphomas: a diagnostic overview of key histomorphologic, immunophenotypic, and genetic features. Diagnostics (Basel) 2020;10(12):1076. DOI: 10.3390/diagnostics10121076

25. deGroen R.A.L., Schrader A.M.R., Kersten M.J. et al. MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications. Haematologica 2019;104(12):2337-48. DOI: 10.3324/haematol.2019.227272

26. Wright G.W., Huang D.W., Phelan J.D. et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 2020;37(4):551-68 e514. DOI: 10.1016/j.ccell.2020.03.015

27. Wagener R., Seufert J. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood 2019;133(9):962-6. DOI: 10.1182/blood-2018-07-864025

28. Smith M.C., Kressin M.K., Crawford E. et al. B lymphoblastic leukemia with a novel t(11;15) (q23;q15) and unique Burkittoid morphologic and immunophenotypic findings in a 9-year-old boy. Lab Med Fall 2015;46(4):320-6. DOI: 10.1309/LM0BOC84GSQGHYKD

29. Greenough A., Dave S.S. New clues to the molecular pathogenesis of Burkitt lymphoma revealed through next-generation sequencing. Curr Opin Hematol 2014;21(4):326-32. DOI: 10.1097/MOH.0000000000000059

30. Giulino-Roth L., Wang K. Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 2012;120(26):5181-4. DOI: 10.1182/blood-2012-06-437624.

31. Love C., Sun Z., Jima D. et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012;44(12):1321-5. DOI: 10.1038/ng.2468

32. Helming K.C., Wang X. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell 2014;26(3):309-17. DOI: 10.1016/j.ccr.2014.07.018

33. Bogershausen N., Wollnik B. Mutational landscapes and phenotypic spectrum of SWI/SNF-related intellectual disability disorders. Front Mol Neurosci 2018;11:252. DOI: 10.3389/fnmol.2018.00252

34. Dhodapkar M.V. Navigating the Fas lane to improved cellular therapy for cancer. J Clin Invest 2019;129(4):1522-3. DOI: 10.1172/JCI127581

35. Rimsza L.M., Roberts R.A., Campo E. et al. Loss of major histocompatibility class II expression in non-immune privileged site diffuse large B cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 2006;107:1101-7. DOI: 10.1182/blood-2005-04-1510

36. Blagih J., Buck M.D. p53, cancer and the immune response. J Cell Sci 2020;133(5):jcs237453. DOI: 10.1242/jcs.237453

37. Cortez M.A., Ivan C., Valdecanas D. et al. PDL1 regulation by p53 via miR-34. J Natl Cancer Inst 2016;108:djv303.. DOI: 10.1093/jnci/djv303

38. Broseus J., Chen G., Valdecanas D. et al. Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. Oncotarget 2016;7(51):83987-4002. DOI: 10.18632/oncotarget.9793

39. Lee B., Lee H., Cho J. et al. Mutational profile and clonal evolution of relapsed/refractory diffuse large B-cell lymphoma. Front Oncol 2021;11:628807. DOI: 10.3389/fonc.2021.628807

40. Coccaro N., Anelli L., Zagaria A. et al. Molecular complexity of diffuse large B-cell lymphoma: can it be a roadmap for precision medicine? Cancers 2020;12(1):185. DOI: 10.3390/cancers12010185

41. Angeli E., Nguyen T.T., Janin A. et al. How to make anticancer drugs cross the blood-brain barrier to treat brain metastases. Int J Mol Sci 2019;21(1):22. DOI: 10.3390/ijms21010022

42. Tsang M., Rubenstein J.L., Rubenstein J.L. Primary central nervous system lymphoma in older adults and the rationale for maintenance strategies: a narrative review. Ann Lymphoma 2021;5:25. DOI: 10.21037/aol-20-43

43. Mukasa A. Genome medicine for brain tumors: current status and future perspectives. Neurol Med Chir 2020;60(11):531-42.. DOI: 10.2176/nmc.ra.2020-0175

44. Haile W.B., Gavegnano C., Tao S. et al. The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Neurobiol Dis 2016;92(Pt. B):137-43. DOI: 10.1016/j.nbd.2016.02.007

45. Annese T., Tamma R., De Giorgis M. et al. RNAscope dual ISH-IHC technology to study angiogenesis in diffuse large B-cell lymphomas. Histochem Cell Biol 2020;153(3):185-92. DOI: 10.1007/s00418-019-01834-z

46. Rubenstein J.L., Geng H., Fraser E.J.. et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2018;2(13):1595-607. DOI: 10.1182/bloodadvances.2017014845

47. Ghesquieres H., Chevrier M., Laadhari M. et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/ refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). Ann Oncol 2019;30(4):621-8. DOI: 10.1093/annonc/mdz032

48. De Groen R.A.L., Schrader A.M.R., Kersten M.J. et al. MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications. Vermaat Haematologica 2019;104(12):2337-48. DOI: 10.1093/annonc/mdz032

49. Wudhikarn K., Pennisi M., Garcia-Recio M. et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv 2020;4(13):3024-33. DOI: 10.1182/bloodadvances.2020001972

50. Nayak L., Iwamoto F.M., LaCasce A. et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 2017;129(23):3071-3. DOI: 10.1182/blood-2017-01-764209

51. Grommes C., Nayak L., Tun H.W., Batchelor T.T. Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol 2019;21(3):306-13. DOI: 10.1093/neuonc/noy193

52. Wellenstein M.D., de Visser K.E. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 2018;48(3): 399-416. DOI: 10.1016/j.immuni.2018.03.004

53. Яшин К.С., Медяник И.А. Иммунотерапия злокачественных опухолей головного мозга (обзор). СТМ 2014;6(4):189-200.